The motivations, barriers, and sociodemographic characteristics of healthy Chinese volunteers in phase I research

被引:4
作者
Wang, Zejuan [1 ]
Chen, Gang [1 ]
Liu, Xiaona [1 ]
Liu, Chen [2 ]
Song, Qingkun [3 ]
Wang, Jin [1 ]
机构
[1] Aerosp Ctr Hosp, Dept Clin Pharmacol, 15 Yuquan Rd, Beijing 100049, Peoples R China
[2] Capital Med Univ, Beijing Shijitan Hosp, Phase Clin Trial Ctr 1, 10 Tieyi Rd, Beijing 100038, Peoples R China
[3] Capital Med Univ, Beijing Shijitan Hosp, Dept Sci & Technol, 10 Tieyi Rd, Beijing 100038, Peoples R China
关键词
Healthy volunteers; Recruitment; Participation; Motivations; Barriers; Willingness; CLINICAL-RESEARCH; PARTICIPATE; WILLINGNESS; ATTITUDES; DECISION; MOTIVES; PAYMENT; TRIALS; RISKS;
D O I
10.1007/s00228-020-03040-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose To describe the motivations, barriers, and sociodemographic characteristics of healthy Chinese volunteers in phase I research and to demonstrate the factors influencing their willingness to participate in subsequent trials. Methods Healthy subjects who participated in seven phase I trials at two centres were invited to participate in the cross-sectional survey at discharge by anonymously and voluntarily completing the self-administered questionnaire. Results From 442 subjects asked to complete the questionnaire, a response rate of 94.8% (419) was obtained, and 72.8% of the respondents had participated in a mean of 2.0 +/- 1.3 previous studies. Over 90% of the subjects indicated that the main motivations to participate trials were to help more people, to contribute to scientific research, and to obtain money. The top 5 barriers were time inconvenience, advertisement sources, potential risks associated with the drug, privacy, and the route of drug administration. Nearly half (49.6%) of the subjects were willing to participate in the next trial. The factors impacting the willingness of the subjects to participate in subsequent trials were gender, screening frequency, enrolment frequency, level of understanding of the research, two motivating factors (to make money and receive a free check-up), and ten barriers (e.g. risk, distance, living conditions, and trust). Conclusions The majority of healthy Chinese subjects were young, were less well educated, had low income levels, and had poor medical insurance coverage. Given the multiple sources of motivation and complex barriers to trial participation, investigators and recruitment staff should consider ethics aspects to guarantee volunteer safety and well-being.
引用
收藏
页码:557 / 568
页数:12
相关论文
共 44 条
  • [1] Study design attributes influenced patients' willingness to participate in clinical research: a randomized vignette-based study
    Agoritsas, Thomas
    Deom, Marie
    Perneger, Thomas V.
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2011, 64 (01) : 107 - 115
  • [2] Patients' decision-making process regarding participation in phase I oncology research
    Agrawal, Manish
    Grady, Christine
    Fairclough, Diane L.
    Meropol, Neal J.
    Maynard, Kim
    Emanuel, Ezekiel J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (27) : 4479 - 4484
  • [3] Almeida L, 2008, INT J CLIN PHARM TH, V46, P574
  • [4] Almeida L, 2008, INT J CLIN PHARM TH, V46, P109
  • [5] Who volunteers for phase I clinical trials? Influences of anxiety, social anxiety and depressive symptoms on self-selection and the reporting of adverse events
    Almeida, Luis
    Kashdan, Todd B.
    Nunes, Teresa
    Coelho, Rui
    Albino-Teixeira, Antonio
    Soares-da-Silva, Patricio
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (06) : 575 - 582
  • [6] Why healthy subjects volunteer for phase I studies and how they perceive their participation?
    Almeida, Luis
    Azevedo, Benedita
    Nunes, Teresa
    Vaz-da-Silva, Manuel
    Soares-da-Silva, Patricio
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (11) : 1085 - 1094
  • [7] WEIGHT OF FINANCIAL REWARD IN THE DECISION BY MEDICAL-STUDENTS AND EXPERIENCED HEALTHY-VOLUNTEERS TO PARTICIPATE IN CLINICAL-TRIALS
    BIGORRA, J
    BANOS, JE
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 38 (05) : 443 - 446
  • [8] CAO Yuming., 2017, Herald of Medicine, P226
  • [9] Center for drug evaluation,NMPA, 2020, TOT NUMB REG YARL
  • [10] Phase 1 healthy volunteer willingness to participate and enrollment preferences
    Chen, Stephanie C.
    Sinaii, Ninet
    Bedarida, Gabriella
    Gregorio, Mark A.
    Emanuel, Ezekiel
    Grady, Christine
    [J]. CLINICAL TRIALS, 2017, 14 (05) : 537 - 546